- Made available online as an Accepted Preprint 6 December 2010
- Accepted Preprint first posted online on 6 December 2010
Drug transporters, the blood–testis barrier, and spermatogenesis
- The Mary M Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Avenue, New York, New York 10065, USA
- (Correspondence should be addressed to C Y Cheng; Email: y-cheng{at}popcbr.rockefeller.edu)
Abstract
The blood–testis barrier (BTB), which is created by adjacent Sertoli cells near the basement membrane, serves as a ‘gatekeeper’ to prohibit harmful substances from reaching developing germ cells, most notably postmeiotic spermatids. The BTB also divides the seminiferous epithelium into the basal and adluminal (apical) compartment so that postmeiotic spermatid development, namely spermiogenesis, can take place in a specialized microenvironment in the apical compartment behind the BTB. The BTB also contributes, at least in part, to the immune privilege status of the testis, so that anti-sperm antibodies are not developed against antigens that are expressed transiently during spermatogenesis. Recent studies have shown that numerous drug transporters are expressed by Sertoli cells. However, many of these same drug transporters are also expressed by spermatogonia, spermatocytes, round spermatids, elongating spermatids, and elongated spermatids, suggesting that the developing germ cells are also able to selectively pump drugs ‘in’ and/or ‘out’ via influx or efflux pumps. We review herein the latest developments regarding the role of drug transporters in spermatogenesis. We also propose a model utilized by the testis to protect germ cell development from ‘harmful’ environmental toxicants and xenobiotics and/or from ‘therapeutic’ substances (e.g. anticancer drugs). We also discuss how drug transporters that are supposed to protect spermatogenesis can work against the testis in some instances. For example, when drugs (e.g. male contraceptives) that can perturb germ cell adhesion and/or maturation are actively pumped out of the testis or are prevented from entering the apical compartment, such as by efflux pumps.
Introduction
In the mammalian testis, as in rats, spermatogenesis is a complex cellular event that takes place in the seminiferous epithelium of seminiferous tubules. During spermatogenesis the spermatogonia (2n) undergo mitosis, followed by a cellular transformation from type B spermatogonia into spermatocytes, which enter meiosis to form spermatids (1n), and finally develop to spermatozoa via spermiogenesis. Hormonally, spermatogenesis is supported by two pituitary hormones, namely the FSH and LH. FSH exerts its effects on Sertoli cells, whereas LH regulates steroidogenesis in Leydig cells in the interstitium (Sharpe 1994, Cheng & Mruk 2010b) which are involved in the production of testosterone and estrogens to regulate spermatogenesis (Shaha 2008, Carreau & Hess 2010, Carreau et al. 2010). In short, spermatogenesis is composed of i) mitotic renewal of spermatogonial stem cells and spermatogonia, ii) transformation of type B spermatogonia to preleptotene spermatocytes, iii) transit of preleptotene spermatocytes across the blood–testis barrier (BTB), iv) meiosis, v) differentiation of round spermatids to spermatozoa via spermiogenesis, and vi) spermiation. The BTB anatomically divides the seminiferous epithelium into the basal and the apical compartment. As such, the entire event of postmeiotic germ cell development, namely spermiogenesis, and spermiation take place behind the BTB in the apical compartment. Spermatids differentiate into spermatozoa by undergoing a series of 19, 16 and 6 transformation steps in rats, mice and men, respectively, with profound morphological changes including the formation of the acrosome, condensation of genetic materials into the spermatid head, and the elongation of the tail (de Kretser & Kerr 1988, Hess & de Franca 2008, Cheng & Mruk 2010b). Additionally, the BTB confers, at least in part, immune privilege status to the testis (Meinhardt & Hedger 2010) in order to avoid the production of auto-antibodies against antigens on spermatocytes and spermatids, many of which are expressed transiently during spermatogenesis. We discuss herein the critical function of drug transporters (both efflux and influx pumps) in the testis and their role at the BTB in relation to spermatogenesis.
BTB structure and function
The BTB is one of the tightest blood-tissue barriers known to exist in mammalian tissues. Unlike other blood-tissue barriers, such as the blood–brain and the blood–retina barriers which constitute almost exclusively tight junctions (TJs) between endothelial cells, the BTB – most notably in rodents, primates, and humans – is constituted of coexisting specialized junctions between Sertoli cells near the basement membrane, which include TJs, basal ectoplasmic specializations (basal ESs), gap junctions (GJs), and desmosome-like junctions (Wong & Cheng 2005, Cheng & Mruk 2009, 2010b, Li et al. 2009, Cheng et al. 2010; see Fig. 1 and Table 1). The endothelial TJs in microvessels found in the interstitium between seminiferous tubules in the testis, however, contribute relatively little barrier function of the BTB. Furthermore, basal ESs that coexist with TJs at the BTB are typified by the presence of actin filament bundles sandwiched between the plasma membrane of Sertoli cells and cisternae of endoplasmic reticulum (see Fig. 1), making BTB a unique blood–tissue barrier ultrastructure (for a review, see Cheng & Mruk (2010b)). Additionally, the BTB anatomically segregates the seminiferous epithelium into basal and apical (or adluminal) compartments (see Fig. 1) so that postmeiotic spermatid development (i.e. spermiogenesis) and spermiation take place in a specialized microenvironment behind the BTB. In short, the BTB creates an immunological barrier, so that antigens, many of which appear transiently during spermiogenesis, are sequestered from the systemic circulation to avoid the production of anti-sperm antibodies. In fact, this ultrastructure determines in large part the nutrients, ions, electrolytes, as well as hormonal, paracrine, and autocrine factors having access to the developing spermatids in the apical compartment. This is known as the ‘barrier’ function of the BTB. Furthermore, the BTB confers cell polarity (Wong & Cheng 2009, Cheng & Mruk 2010b) resulting in the nuclei of Sertoli cells being located near the basement membrane.
A schematic drawing illustrating the relative distribution of drug transporters, both influx and efflux pumps, in the seminiferous epithelium of adult rat testes. It is noted that both efflux pumps (e.g. P-glycoprotein) and influx pumps (e.g. OATP, OAT, and OCT) are found at the BTB and the apical ES, associated with the integral membrane proteins localized to either Sertoli cells at the BTB or Sertoli and elongating spermatids at the apical ES. Full colour version of this figure available via http://dx.doi.org/10.1677/JOE-10-0363.
Different junction types in the testis and the drug transporters found in these junctions
As noted above, the BTB is constituted by coexisting TJs, basal ESs, GJs, and desmosome-like junctions. It was thought that the ‘barrier’ function imposed by the BTB restricted the flow of substances including drugs across this immunological barrier. However, recent studies have demonstrated that the BTB is a highly dynamic ultrastructure, undergoing extensive restructuring at stages VIII–IX of the epithelial cycle thereby facilitating the transit of preleptotene spermatocytes across the BTB (Cheng & Mruk 2010b, Mruk & Cheng 2010). In addition, there are numerous drug transporters (including efflux and influx pumps) in Sertoli cells, that are known to structurally associate with TJ protein complexes at the BTB (see Table 1). These transporters determine which drugs have access to the developing germ cells in the apical compartment behind the BTB (Fig. 1). Recent studies by dual-labeled immunofluorescence analysis have shown that P-glycoprotein (an efflux pump) is co-localized with several BTB constituent proteins, such as TJ-proteins (occludin, claudin-11, JAM-A, and ZO-1) and basal ES-proteins (N-cadherin and β-catenin) (Su et al. 2009). Moreover, the putative interaction of these drug transporters with proteins at the BTB was confirmed by co-immunoprecipitation experiments that demonstrated the association between P-glycoprotein and several BTB integral membrane proteins. Interestingly, an increase in association between P-glycoprotein and some BTB proteins (e.g. occludin, claudin-11, and JAM-A) was detected after treatment with adjudin (Su et al. 2009) 1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide, a potential male contraceptive drug known to induce germ cell loss from the adult testis in rats, rabbits, and dogs (Cheng et al. 2005, Mruk et al. 2008, Hu et al. 2009, Cheng & Mruk 2010c) suggesting that P-glycoprotein forms a structural complex with occludin, claudin-11, and JAM-A at the BTB, which may take part in the process of regulating the drug concentration in the apical compartment of the seminiferous epithelium, similar to its ‘gatekeeper’ role at the blood–brain barrier (BBB; Schinkel 1999).
Drug transporters in the testis
Drug transporters are ubiquitously expressed in tissues and organs, such as the testis, kidney, liver, brain, and intestine, and they are crucial to drug absorption, disposition, metabolism, and excretion. The amount of drugs (e.g. adjudin), xenobiotics (e.g. cadmium, and bisphenol A), and other chemicals (e.g. mercury and lead) that enter different tissues and/or organs in mammals under physiological and pathological conditions are determined by drug transporters. About 60% of the ∼800 drug transporters known to exist are integral membrane proteins that transport or prevent the transport of xenobiotics across biological membranes in cell epithelia and endothelia in mammals (Dallas et al. 2006, Rochat 2009, Franke et al. 2010, Kis et al. 2010). For instance, it is known that the entry of cadmium into the seminiferous epithelium behind the BTB requires the presence of ZIP8, a zinc transporter also known as SLC39A8 in mice (Dalton et al. 2005).
Drug transporters are classified either as primary active transporters that require ATP hydrolysis for function, or as secondary and tertiary active transporters driven by ion exchange or co-transport without the consumption of ATP. Owing to the growing number of drug transporters, the HUGO Gene Nomenclature Committee has classified all transporter proteins into two broad categories: i) ATP-binding cassette (ABC) and ii) solute carrier (SLC; see Tables 2 and 3). Both groups consist of many subfamily members that are involved in the transport of a broad range of drugs or substrates (see Table 2). Alternatively, drug transporters can be broadly classified as either influx or efflux pumps. These are defined solely by the direction in which they transport substrates or drugs. For instance, influx pumps (e.g. organic anion transporter (OAT)/organic anion-transporting polypeptide (OATP) and organic cation transporter (OCT)/organic cation transporting polypeptide (OCTP)) transport drugs into cells, whereas efflux pumps (e.g. P-glycoprotein, multidrug resistance protein-related proteins (MRPs), and breast cancer resistance protein (BCRP)) transport drugs out of cells and can also prevent the entry of ‘unwanted’ drugs into a cell (see Tables 2 and 3). Efflux pumps, thus, determine the amount of a drug inside a cell. The effect of efflux pumps are often realized in cancer patients who do not respond to chemotherapeutic drugs wherein tumor cells actively pump chemotherapeutic drugs out of the developing or metastatic tumor. The properties of drug transporters are important to consider in drug design because they play key roles in determining the bioavailability, pharmacokinetics, and efficacy of drugs. Furthermore, drugs can be designed to avoid certain tissues if these tissues lack specific influx transporters, thereby reducing adverse side effects and toxicity (Alam et al. 2010, Ganta et al. 2010, Gaucher et al. 2010, Kis et al. 2010). On the other hand, drugs may be developed or modified to target selected tissues that overexpress specific drug transporters following their exposure to certain drugs (Fardel & Le Vee 2009, Yu et al. 2010). For the development of nonhormonal contraceptives for males, a better understanding of drug transporters in the testis is particularly important, since many compounds under investigation exert their effects behind the BTB, and have low bioavailability, due to the interactions between these drugs and drug transporters in the testis. We summarize below some of the latest findings in the field regarding drug transporters that are pertinent to our current investigation in developing novel compounds for male contraception.
Transporters with relatively high expression and/or that have an important role in the testis
Selected drug transporters found in different blood–tissue barriers and their known substrates
ABC transporter superfamily in the testis
Virtually all ABC transporters in mammalian epithelial and/or endothelial cells are efflux pumps (see Tables 2 and 3). ABC transporters utilize a primary active transport (also known as a direct active transport) mechanism, which uses ATP directly as the energy source to actively transport drugs across the plasma membrane against a concentration gradient. Many ABC transporters are expressed at the BTB (Tables 2 and 3). There are three well-studied drug transporters in the ABC superfamily: i) multidrug resistance proteins (MDRs), ii) MDR-related proteins (MRPs), and iii) BCRP, which are discussed here (Tables 2 and 3). The ABC genes are divided into seven subfamilies of ABC1, MDR/TAP (TAP, transporter, ABC, sub-family B), MRP, ALD (not Abcd1), OABP (ABC, sub-family E), GCN20 (ABC, sub-family F), and WHITE (specifically for sterol or possibly for cholesterol transport; Dean et al. 2001, Fitzgerald et al. 2010, Green 2010, Shen & Zhang 2010, Tomi & Hosoya 2010).
Multidrug resistance proteins
The concept of multidrug resistance originated from studies in cancer biology (Dallas et al. 2006, Shukla et al. 2010). During chemotherapy, cancer cells develop resistance to anticancer drugs. Even though many of these drugs are structurally and functionally unrelated, cancer cells will gain the ability to actively pump these drugs out of the developing tumors and/or prevent the entry of these drugs to tumor cells. This phenomenon is known as multidrug resistance. Subsequent studies have shown that multidrug resistance is mediated by integral membrane proteins known as MDRs. MDRs are efflux pumps that actively pump chemotherapeutic drugs out of cancer cells, or simply prevent their entry into cells, and are also found in normal epithelial and endothelial cells in mammals (Rochat 2009, Ni et al. 2010, Shukla et al. 2010).
The best-studied MDR is the P-glycoprotein (Miller et al. 2008, Li et al. 2010, Miller 2010). There are three separate P-glycoprotein-encoding genes found in rodents, namely multidrug resistance 1 gene Mdr1 (or Mdr1b), Mdr2, and Mdr3 (or Mdr1a). However, only Mdr1 and Mdr3 encode the MDR phenotype of P-glycoprotein (Couture et al. 2006, Miller et al. 2008, Setchell 2008, Crowley & Callaghan 2009). Although Mdr2 shows a 85% amino acid homology with Mdr1 (Gros et al. 1988), Mdr2 transports hepatic phospholipids into bile, and is not an efflux pump (Smit et al. 1993). In the testis, Mdr3 is highly expressed (Croop et al. 1989), and is detected in Sertoli cells, Leydig cells, peritubular myoid cells, and late spermatids, but not in spermatogonia, spermatocytes, or early spermatids (Melaine et al. 2002, Bart et al. 2004). In humans, P-glycoprotein is the product of MDR1 (ABCB1) and MDR2 (ABCB4; van der Bliek et al. 1988), with MDR2 functioning as a phosphatidyl translocase in the liver instead of a drug transporter (Ruetz & Gros 1994).
P-glycoprotein was first discovered in cancer cells showing resistance to diverse classes of chemotherapy drugs whose structures did not share any similarities (Schinkel & Jonker 2003, Fromm 2004, Leslie et al. 2005). In short, P-glycoprotein pumps therapeutic drugs out of tumor cells that recognize these drugs as ‘harmful.’ Subsequent studies have shown that P-glycoprotein is also found in many normal tissues and cells, such as in small intestine (Muller et al. 2003), in endothelial cells that constitute the BBB (Miller et al. 2008, Miller 2010), and in Sertoli cells that create the BTB (Su et al. 2009). In the testis, P-glycoprotein is also found in late spermatids, but not spermatogonia, spermatocytes, or early spermatids (Melaine et al. 2002). This finding is somewhat in contrast to the result of Trezise et al. (1992) who reported that P-glycoprotein is detected in spermatogonia and endothelial cells in micro vessels in rat testes.
The substrates of P-glycoprotein include a wide variety of therapeutic drugs, such as anticancer drugs, antihypertensive agents, antidepressants, antibiotics, antimycotics, antiviral agents, immunosuppressants, and others (Marzolini et al. 2004, Dallas et al. 2006; Table 3). Some of these drugs also serve as inhibitors for P-glycoprotein (Marzolini et al. 2004). It is also possible that many drugs interact with P-glycoprotein at different binding sites (Ford 1995).
In the testis, P-glycoprotein is an integrated component of occludin-, claudin-11-, and JAM-A-based TJ-protein complexes, as well as of the N-cadherin-based basal ES-protein complex at the BTB (Su et al. 2009). Accordingly, studies by immunohistochemistry and dual-labeled immunofluorescence analysis have shown that P-glycoprotein is expressed abundantly in the seminiferous epithelium near the basement membrane and it co-localizes with occludin, claudin-11, JAM-A, and N-cadherin (Su et al. 2009). However, P-glycoprotein staining was also detected at the apical ES at the Sertoli cell–spermatid interface (Su et al. 2009). It also appears that the localization of P-glycoprotein at the BTB in the seminiferous epithelium is not stage specific since a relatively high level of expression was detected during the entire seminiferous epithelial cycle (Su et al. 2009). More importantly, the BTB integral membrane proteins were found to structurally interact with P-glycoprotein as demonstrated by co-immunoprecipitation experiments. Furthermore, P-glycoprotein became more tightly associated with occludin, claudin-11, and JAM-A following exposure of rats to adjudin (Su et al. 2009), an agent that is known to induce germ cell, in particular spermatid, depletion from the seminiferous epithelium (for a review, see Mruk et al. (2008)). These findings support a notion that, with the other BTB proteins, the P-glycoprotein acts as a ‘gatekeeper’ for adjudin entrance (see Fig. 2), a drug harmful for germ cell adhesion in the apical compartment, out of the seminiferous epithelium actively or to prevent the entry of adjudin into the apical compartment. These findings are in agreement with the extremely low bioavailability of adjudin, a potential male contraceptive being actively pursued in our laboratory (Mruk et al. 2008, Cheng & Mruk 2010c), making it somewhat difficult to deliver this and other related drugs to the apical compartment so that they can induce premature release of germ cells, without perturbing the hypothalamic–pituitary–testicular axis.
A schematic drawing illustrating the role of drug transporters in regulating the amount of drugs (e.g. adjudin) that can gain entry to the adluminal (apical) compartment in the seminiferous epithelium. The upper left panel shows the molecular architecture of some of the known integral membrane proteins at the BTB, such as occludin, claudins (e.g. claudin-1, claudin-5, and claudin-11), JAMs (e.g. JAM-A and JAM-B), and the association of efflux pumps (e.g. P-glycoprotein) and/or influx pumps (e.g. OATP, OAT, and OCT) with some of these integral membrane proteins (Cheng & Mruk 2010b, Morrow et al. 2010, Mruk & Cheng 2010). When the animals or humans are exposed to toxicants and/or drugs, such as adjudin, these compounds enter the seminiferous epithelium via influx pumps (e.g. OATP drug transporters; see middle left panel). It was reported that when rats were exposed to adjudin (a single dose at 50 mg/kg b.w. via gavage), a surge in P-glycoprotein steady-state protein level by as much as fourfold was detected within 6–12 h following drug treatment, which was accompanied by a sixfold increase in the association between P-glycoprotein and the occludin–ZO-1 protein complex within 9–12 h after drug treatment, so that ‘unwanted’ harmful adjudin could be pumped outside cells (both Sertoli and developing germ cells) or prevented from entering cells in the seminiferous epithelium (see lower left panel). This thus provides a unique mechanism to protect the testes from unwanted harmful substances reaching the developing spermatids in the apical compartment behind the BTB. However, some adjudin molecules may still enter the BTB, perhaps via the influx pumps (or via diffusion) and can have access to the apical ES in developing spermatids (see lower right panel). Adjudin likely exerts its effects by enhancing protein endocytosis (see middle right panel) and subsequent endosome-mediated protein degradation (see upper right panel), thereby destabilizing the apical ES. This, in turn, leads to germ cell (e.g. elongating spermatids) loss from the seminiferous epithelium. Full colour version of this figure available via http://dx.doi.org/10.1677/JOE-10-0363.
Multidrug resistance-related proteins
MRP is another efflux transporter subfamily of the ABC transporters, which is distantly related to P-glycoprotein. There are three members of the MRP family showing drug-transporting capability. They are MRP1 (ABCC1), MRP2 (ABCC2), and MRP3 (ABCC3), which were initially found in human tumor cells (see Table 3). Members of the MRP subfamily appear to have overlapping substrate specificities, but differ in their kinetic properties (Keppler et al. 1999). MRP1 is ubiquitously present in many tissues, including rodent testes, where it is mostly expressed in the basal compartment of the Sertoli cells (Wijnholds et al. 1998, Bart et al. 2004) and in Leydig cells (Bart et al. 2004). MRP2 and MRP3 are found mostly in liver and kidney but MRP2 is absent in the brain (Keppler et al. 1999). All the MRP proteins are localized to the basolateral membrane of polarized epithelial cells (Flens et al. 1996, Schaub et al. 1997, König et al. 1999, Kool et al. 1999).
MRP1 is a glycosylated and phosphorylated transmembrane protein with an apparent Mr of 190 kDa. While MRP1 is an efflux drug transporter, it shares only 15% amino acid homology with P-glycoprotein. However, the partial overlap in substrate specificity indicates that MRP1 and P-glycoprotein are functionally similar. Besides anticancer drugs and antibiotics, MRP1 also transports many naturally occurring compounds, such as GSH, GSH disulfide, glucuronide, and several sulfate conjugates out of cells (Lautier et al. 1996, Loe et al. 1996). Furthermore, MRP1 can transport metals from the cells across the plasma membrane, including sodium arsenate and antimony potassium tartrate (Lorico et al. 2002). This function illustrates its protective role against environmental metal-based toxicants.
Similar to P-glycoprotein knockout mice, Mrp(−/−) mice did not display embryonic death nor any changes in fertility as compared to wild-type mice (Rappa et al. 1999). However, etoposide-phosphate (ETOPOPHOS)-treated (an antineoplastic agent) Mrp(−/−) mice had a significant reduction in testis weight, as well as a severe disruption in spermatogenesis: the mice were devoid of meiotic division, displayed the presence of round spermatids in the tubule lumen, and presented with very few spermatozoa in the epididymis as compared with drug-treated wild-type mice (Wijnholds et al. 1998). It should be noted that the ETOPOPHOS-treated wild mice also showed a disruption in spermatogenesis, but meiotic divisions still occurred, and the epididymis contained many normal spermatozoa, plus some prematurely released round spermatids. Taking these data collectively, Mrp1 appears to possess a protective role in maintaining BTB function, and its deletion impedes spermatogenesis via a loss of BTB function. However, the BTB integrity in these mice remains to be investigated.
Breast cancer resistance protein
BCRP (also known as ABCG2) is expressed in the testis (Bart et al. 2004), being detected in endothelial cells of microvessels and peritubular myoid cells (Bart et al. 2004). BCRP, an efflux pump, is known to limit the penetration of phytoestrogens, such as daidzein, genistein, and coumestrol into the testis as shown in Bcrp−/− mice (Enokizono et al. 2007), indicating its protective role against the adverse effects of phytoestrogens on spermatogenesis (Delclos et al. 2001, Wisniewski et al. 2003, Kyselova et al. 2004). BCRP, similarly to that shown for P-glycoprotein, also limits the penetration of common basic or neutral compounds, such as 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethylimidazol[4,5-f]quinoxaline (MeIQx), prazosin, and triamterene into the brain (Delclos et al. 2001, Wisniewski et al. 2003, Kyselova et al. 2004). However, most BCRP-specific substrates are weak acids (Enokizono et al. 2008). The action of BCRP, thus, complements the activity of P-glycoprotein in excluding acidic xenobiotic compounds from the brain or the testis, illustrating the in vivo significance of BCRP in conferring drug resistance. Another BCRP structurally related protein encoded by the cystic fibrosis gene is also expressed in spermatids but not in endothelial cells (Trezise & Buchwald 1991, Trezise et al. 1992). Until now, there have been no studies carried out regarding this class of efflux pumps in testicular function, in particular their role in spermatogenesis and BTB dynamics.
Solute carrier (SLC) transporter superfamily in the testis
The SLC transporter superfamily is comprised of several subfamilies: OATs, OATPs, OCTs, organic cation/carnitine transporters (OCTNs), as well as peptide transporters, concentrative nucleoside transporters, equilibrative nucleoside transporters, and others. Many of the SLC transporters are efflux pumps, but OATPs, OATs, OCTs, and OCTNs are influx pumps (see Table 2). The SLC transporters typically use a secondary and tertiary active transport mechanism to transport drugs into a cell, this is different from ABC transporters that utilize primary active transport, which directly uses energy (i.e. ATP) to transport drugs across the plasma membrane. In essence, SLC transporters do not use ATP directly, and the energy is derived from a gradient that is created by a primary active transport system, such as the electrochemical potential difference created by pumping ions out of a cell. Alternatively, drugs (e.g. small ionic compounds) or environmental toxicants (e.g. heavy metals) can be transported across ‘pores’ present in SLC transporters, such as OATs or OATPs. SLC transporters play a crucial role in the influx and/or efflux of many organic anionic and cationic compounds in epithelial and endothelial cells. Among the 43 SLC subfamilies, the SLC21/SLCO (OATP) and SLC22 subfamilies (OAT/OCT/OCTN) are two of the best-studied ion transporters (Kalliokoski & Niemi 2009, Fahrmayr et al. 2010, Kis et al. 2010, Klaassen & Aleksunes 2010). We briefly summarize herein a few selected ion transporters relevant to spermatogenesis.
SLC21/SLCO (OATP) subfamily
The SLC21/SLCO subfamily of SLC superfamily is also known as OATP subfamily, with 15 and 10 isoforms of OATP identified in rodents and humans respectively (Kalliokoski & Niemi 2009, Fahrmayr et al. 2010). OATPs are influx pumps responsible for the entry of drugs into cells. However, some OATP members can function as both influx and efflux pumps. For instance, Oatp2 mediates bidirectional transport of organic anions (Li et al. 2000). OATPs mediate transport of a wide spectrum of amphipathic organic anions, and each OATP protein has a predicted membrane topology that comprises 12α-helical transmembrane domains with amino and carboxyl termini embedded within the membrane (Mikkaichi et al. 2004).
OATPs are found in the liver, kidney, lungs, intestine, and testes (see Table 2). In the testis, OATP-F (Slc21a14) is limited to Leydig cells (Pizzagalli et al. 2002), and it mediates the disposition of thyroid hormones in the testis. OATP6B1 (Slco6b1, Tst1) and OATP6C1 (Slco6c1, Tst2) are specifically expressed in the testis, limited to Sertoli cells, spermatogonia, and Leydig cells (Suzuki et al. 2003), and OATP3 (Slc21a7) mRNA is highly expressed in Sertoli cells (Augustine et al. 2005).
The substrates of OATPs include therapeutic drugs (e.g. statins and cardiac glycosides) and endogenous biomolecules (e.g. thyroxine, steroid conjugates, taurocholate, and bile acids). Substrates transported into the bile by hepatic OATPs are usually structurally large chemicals and low extracellular pH was found to enhance OATP transport activity (Leuthold et al. 2009).
OATP3 (Slc21a7) was first isolated from rat retina, it has 670 amino acid residues, and shows 80 and 82% identity with OATP1 and OATP2 respectively (Abe et al. 1998). Oatp3 mRNA has been shown to be highly expressed in the testis (e.g. Sertoli cells), as well as in the liver, kidney, retina, and brain (Abe et al. 1998, Ohtsuki et al. 2004, Augustine et al. 2005). The function of OATP3 is not fully known but it is involved in thyroid hormone and taurocholate transport (Abe et al. 1998). In the brain, studies by immunohistochemistry have shown that OATP3 is localized at the brush-border membrane of mouse choroid plexus epithelial cells, in neural cells, and the olfactory bulb, as well as in brain capillary endothelial cells (Ohtsuki et al. 2004). In the testis, OATP3 is detected at the BTB with highest expression from stages VII to X of the seminiferous epithelial cycle (Su & Cheng, unpublished data).
SLC22 subfamily
This family contains three classes of transporters: OATs, OCTs, and OCTNs (see Table 2). The OAT class has four members: OAT1, OAT2, OAT3, and OAT4, corresponding to SLC22A6, 7, 8, and 11, which can act as efflux or influx pumps, depending on their localization and energy requirement (Pritchard & Miller 1993, Sekine et al. 2000). Sodium-dependent OATs, localized at the basolateral membrane of proximal tubular cells in kidney, are crucial to the reabsorption of anionic substances; while sodium-independent and ATP-required active OATs, which are localized on the luminal site, are primarily involved in the secretion of organic anions (Pritchard & Miller 1993, Sekine et al. 2000).
OCTs are polyspecific cationic transporters and they include OCT1–3 (SLC22A1-3). There are three OCTN members in humans: OCTN1 (SLC22A4), OCTN2 (SLC22A5), and CT2 (SLC22A16), which are responsible for carnitine and/or cation influx (Tamai et al. 2000, 2001, Enomoto et al. 2002). In rodents, another carnitine transporter-OCTN3 has also been cloned (Tamai et al. 2000). OCTs and OCTNs have broad tissue distribution and are found in the liver, kidney, and small intestine. OCT1, OCT3, OCTN1, and OCTN2 are expressed by Sertoli cells in the testis (Klaassen & Aleksunes 2010). However, OCT2 is not detected in the rodent testis or Sertoli cells (Koepsell et al. 2007). OCT3 in rodents and OCT2 in humans are primarily expressed in the testis (Koepsell et al. 2007). OCT1 and OCTN2 are found at the basolateral membrane of Sertoli cells (Kobayashi et al. 2005, Maeda et al. 2007), while OCT3 is detected on the apical site of Sertoli cells (Maeda et al. 2007).
OCTs transport a wide range of structurally different, positively charged molecules, which usually have low Mr of <500 Da (Schmitt & Koepsell 2005). Both the substrates and inhibitors of OCT1–3 are broadly overlapping. Oct1(−/−), Oct2(−/−), Oct3(−/−), and Oct1(−/−)/Oct2(−/−) (double knockout) mice have been generated (Jonker et al. 2001, 2003, Zwart et al. 2001, Jonker & Schinkel 2004). Although these Oct knockout mice were fertile without any obvious defects, the transport of certain substrates and the tissue distribution of these substrates in the liver, kidney, heart, and small intestine were altered.
OCTN2 and OCTN3 are the two l-carnitine transporters, which are highly expressed in the testis (Kobayashi et al. 2007). l-carnitine is an essential factor for sperm maturation and metabolism during the transit of spermatozoa in the epididymis where they acquire motility (Jeulin & Lewin 1996). Studies by immunohistochemistry have shown that OCTN2 and OCTN3 are localized to the distal and proximal portion of sperm tail respectively (Kobayashi et al. 2007), and both of these influx pumps mediate the supply of carnitine and acetylcarnitine to epididymal spermatozoa in mice (Kobayashi et al. 2007). Mutations in the gene encoding OCTN2 have been shown to cause obstructive azoospermia in the epididymis (Yakushiji et al. 2006), illustrating the significance of OCTN influx pumps in fertility.
The role of drug transporters in BTB dynamics and spermatogenesis
As summarized in the above sections, drug transporters, both efflux and influx pumps, are not limited to Sertoli cells that constitute the BTB in the mammalian testis even though Sertoli cells express many of these drug transporters. Instead, different classes of germ cells express high levels of different drug transporters at different stages of the seminiferous epithelial cycle of spermatogenesis (Table 2). These findings seemingly suggest that nature has installed a unique mechanism in the testis to ensure the integrity of spermatogenesis. Besides the BTB in the seminiferous epithelium to segregate the events of postmeiotic germ cell development from the systemic circulation, developing spermatids have the ability to pump harmful substances outside these cells and to selectively uptake substances necessary for their development. Furthermore, germ cells (e.g. preleptotene spermatocytes, undifferentiated and differentiated spermatogonial stem cells) that lie outside the BTB also express many drug transporters (Table 2). Recent studies have also demonstrated the unique role of drug transporters in spermatogenesis, as depicted in Fig. 2. It is known that the BTB is constituted by different TJ integral membrane proteins: occludin, claudins (e.g. claudin-1, -5, and -11), and JAMs (e.g. JAM-A and JAM-B; Fig. 2; Cheng & Mruk 2010b, Morrow et al. 2010, Mruk & Cheng 2010). Interestingly, P-glycoprotein was shown to associate with some of the integral membranes proteins at the BTB including occludin, claudin-11, and JAM-A (Su et al. 2009). When testes were exposed to toxicants, such as adjudin, the expression of P-glycoprotein was induced and the association of P-glycoprotein with occludin, claudin-11, and JAM-A was also significantly ‘enhanced’. We hypothesize that this increase in protein-protein associations between P-glycoprotein and integral membrain proteins at the BTB may assist in ‘sealing’ the TJ-barrier at the BTB by pumping or keeping unwanted adjudin molecules out of the apical compartment (Fig. 2). However, adjudin, and possibly other environmental toxicants (e.g. cadmium) that manage to enter the apical compartment likely via other influx drug transporters, can still induce disruption of spermatid adhesion, analogous to the events of spermiation to allow premature release of spermatids from the epithelium. The hypothetical model depicted in Fig. 2 thus suggests that much research is needed to understand the biology and regulation of drug transporters in the testis in order to protect the testes from toxicant-induced testicular injury. However, drug transporters that ‘safeguard’ the immunological barrier (see Fig. 2) also pose a challenge for delivering contraceptives (e.g. adjudin) to the apical compartment of the epithelium behind the BTB to exert their effects (Cheng et al. 2005, Cheng & Mruk 2010a). In short, influx and efflux pumps are acting in concert to determine the amount of drugs (e.g. male contraceptives and anticancer drugs) and/or harmful substances (e.g. environmental toxicants) available in the seminiferous epithelium behind the BTB, analogous to the treatment of tumorigenesis and metastasis using chemotherapeutic drugs (Rochat 2009).
Concluding remarks and future perspectives
It is becoming increasingly clear that drug transporters are not limited to Sertoli cells in the testis that constitute the BTB. This illustrates that the developing germ cells are actively involved in ‘pumping out’ unwanted harmful substances from the seminiferous epithelium or preventing the entry of toxicants into developing germ cells, as well as in ‘selecting/uptaking’ necessary compounds for their development. However, the fact that there are a number of different types of drug transporters (see Table 2) in the testisicular Sertoli, Leydig, germ, and peritubular myoid cells (and it is obvious that many more drug transporters remain to be identified), poses a great challenge to the testis to protect spermatogenesis from harmful compounds and toxicants. For instance, a harmful substance/toxicant can gain entry to the apical compartment, traversing the BTB, via selected influx pumps even though they have been ‘blocked’ to cross the BTB by other efflux or influx pumps or they have been actively pumped out of Sertoli cells and/or germ cells. Once these toxicants enter the seminiferous epithelium, they can exert their effects rapidly by perturbing the actin cytoskeletal network (e.g. perturbing actin bundling or inducing actin nucleation) and accelerate protein endocytosis at the apical ES to cause the unwanted cascade of events analogous to spermiation that leads to premature germ cell exfoliation from the testis and possibly infertility. In short, this is a highly neglected area of research in male reproductive biology that requires additional studies.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
Studies performed in the authors' laboratory discussed herein were supported by grants from the National Institutes of Health (NICHD R01 HD056304 and R01 HD056034-02S1 to C Y C; U54 HD029990 Project 5 to C Y C; and R03 HD061401 to D D M). Due to space limitations, many of the important original research articles by colleagues and investigators in the field could not be cited, and recent reviews on appropriate subjects were used instead.
Author contribution statement
L S researched the topic and co-wrote the review; D M critically evaluated information and co-wrote the review; C Y C conceived the idea to prepare the review, researched the topic, critically evaluated information, and co-wrote the review.
- Received in final form 22 November 2010
- Accepted 6 December 2010
- © 2011 Society for Endocrinology
References
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
